--- title: "4,211,659 Shares in Septerna, Inc. $SEPN Acquired by Trv Gp Vi LLC" type: "News" locale: "en" url: "https://longbridge.com/en/news/296341704.md" description: "Trv Gp Vi LLC acquired a new position in Septerna, Inc. (NASDAQ:SEPN), purchasing 4,211,659 shares valued at approximately $141 billion during the second quarter, per SEC 13F filings. This stake represents 60.7% of Trv Gp Vi's portfolio and 9.34% of Septerna. Other major investors like Goldman Sachs, BlackRock, and Vanguard also increased their holdings. Meanwhile, analysts have raised price targets with an average 'Moderate Buy' rating, while insiders recently sold shares." datetime: "2026-08-19T10:40:47.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296341704.md) - [en](https://longbridge.com/en/news/296341704.md) - [zh-HK](https://longbridge.com/zh-HK/news/296341704.md) generator: "portal-rs" --- # 4,211,659 Shares in Septerna, Inc. $SEPN Acquired by Trv Gp Vi LLC Trv Gp Vi LLC bought a new position in shares of Septerna, Inc. (NASDAQ:SEPN - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 4,211,659 shares of the company's stock, valued at approximately $141,048,460,000. Septerna accounts for 60.7% of Trv Gp Vi LLC's portfolio, making the stock its largest holding. Trv Gp Vi LLC owned 9.34% of Septerna at the end of the most recent quarter. - Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead Several other large investors have also added to or reduced their stakes in SEPN. Goldman Sachs Group Inc. boosted its position in shares of Septerna by 86.6% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,715,129 shares of the company's stock worth $75,698,000 after purchasing an additional 1,260,409 shares during the period. BlackRock Inc. bought a new stake in shares of Septerna during the 2nd quarter valued at $64,706,000. Vanguard Group Inc. raised its position in shares of Septerna by 7.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,518,757 shares of the company's stock valued at $28,568,000 after purchasing an additional 104,394 shares during the period. ADAR1 Capital Management LLC raised its position in shares of Septerna by 38.9% during the 3rd quarter. ADAR1 Capital Management LLC now owns 1,176,491 shares of the company's stock valued at $22,130,000 after purchasing an additional 329,264 shares during the period. Finally, Janus Henderson Group PLC purchased a new position in shares of Septerna during the 1st quarter valued at $21,334,000. ## Wall Street Analysts Forecast Growth SEPN has been the subject of a number of analyst reports. Stifel Nicolaus set a $49.00 price target on Septerna in a research note on Tuesday, August 11th. JonesTrading boosted their price objective on Septerna from $43.00 to $62.00 and gave the company a "buy" rating in a research report on Thursday, August 13th. HC Wainwright upped their price objective on Septerna from $40.00 to $60.00 and gave the stock a "buy" rating in a research note on Wednesday, August 12th. Wells Fargo & Company increased their target price on Septerna from $48.00 to $50.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 12th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Septerna in a research note on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $51.33. - Analysts Think These Stocks Could More Than Double in Value **Check Out Our Latest Stock Analysis on SEPN** ## Insider Buying and Selling at Septerna In other news, COO Elizabeth Bhatt sold 25,000 shares of Septerna stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $44.00, for a total value of $1,100,000.00. Following the sale, the chief operating officer directly owned 174,209 shares of the company's stock, valued at approximately $7,665,196. The trade was a 12.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Samira Shaikhly sold 11,798 shares of the stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $30.06, for a total value of $354,647.88. Following the transaction, the insider directly owned 793 shares of the company's stock, valued at approximately $23,837.58. The trade was a 93.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 72,828 shares of company stock valued at $2,684,314 in the last 90 days. Insiders own 5.80% of the company's stock. ## Septerna Stock Performance - Is It Time to Buy the Dip in Novo Nordisk Stock? SEPN stock opened at $43.80 on Wednesday. The company's fifty day moving average price is $36.37 and its 200-day moving average price is $29.94. Septerna, Inc. has a one year low of $10.74 and a one year high of $51.10. The company has a market capitalization of $2.04 billion, a PE ratio of -81.11 and a beta of 2.29. Septerna (NASDAQ:SEPN - Get Free Report) last posted its earnings results on Monday, August 10th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.14. The company had revenue of $26.75 million during the quarter, compared to analysts' expectations of $19.22 million. Septerna had a negative net margin of 24.51% and a negative return on equity of 9.57%. On average, research analysts predict that Septerna, Inc. will post -1.36 EPS for the current fiscal year. ## Septerna Profile (Free Report) We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body. ## Further Reading - Five stocks we like better than Septerna - The AI Boom Is Turning This Cable Maker Into a Stock to Watch - A Star Investor Just Trimmed Amazon—Here's What It means - Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look - Home Depot Analysts See a Path to $375 and Beyond **Want to see what other hedge funds are holding SEPN?** Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Septerna, Inc. (NASDAQ:SEPN - Free Report). *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in Septerna Right Now? Before you consider Septerna, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Septerna wasn't on the list. While Septerna currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [SEPN.US](https://longbridge.com/en/quote/SEPN.US.md) - [GS-A.US](https://longbridge.com/en/quote/GS-A.US.md) - [BLK.US](https://longbridge.com/en/quote/BLK.US.md) - [GS.US](https://longbridge.com/en/quote/GS.US.md) - [NVO.US](https://longbridge.com/en/quote/NVO.US.md) - [AKRO.US](https://longbridge.com/en/quote/AKRO.US.md) - [LLY.US](https://longbridge.com/en/quote/LLY.US.md) - [JHG.US](https://longbridge.com/en/quote/JHG.US.md) - [WFC.US](https://longbridge.com/en/quote/WFC.US.md) - [W4VR.SG](https://longbridge.com/en/quote/W4VR.SG.md) - [BTX.US](https://longbridge.com/en/quote/BTX.US.md) - [BIT.RT*.US](https://longbridge.com/en/quote/BIT.RT*.US.md) - [BDJ.US](https://longbridge.com/en/quote/BDJ.US.md) - [BSTZ.US](https://longbridge.com/en/quote/BSTZ.US.md) - [BIT.RT.US](https://longbridge.com/en/quote/BIT.RT.US.md) - [WFC-D.US](https://longbridge.com/en/quote/WFC-D.US.md) - [WFC-L.US](https://longbridge.com/en/quote/WFC-L.US.md) - [WFC-Y.US](https://longbridge.com/en/quote/WFC-Y.US.md) - [WFC-C.US](https://longbridge.com/en/quote/WFC-C.US.md) - [WFC-Z.US](https://longbridge.com/en/quote/WFC-Z.US.md) - [WFC-A.US](https://longbridge.com/en/quote/WFC-A.US.md) ## Related News & Research - [Live Oak Investment Partners Takes Position in Encompass Health Corporation $EHC](https://longbridge.com/en/news/296475267.md) - [Compass Financial Management LLC Takes $3.32 Million Position in The Goldman Sachs Group, Inc. $GS](https://longbridge.com/en/news/296877045.md) - [B. Metzler seel. Sohn & Co. AG Invests $4.98 Million in SiTime Corporation $SITM](https://longbridge.com/en/news/296675056.md) - [Goldman Sachs lifts Nagarro voting rights to 5.43% from 4.5%](https://longbridge.com/en/news/296811869.md) - [4,242 Shares in The Travelers Companies, Inc. $TRV Acquired by Peak Asset Management LLC](https://longbridge.com/en/news/296892651.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**